List of Neuraceq drug patents

Neuraceq is owned by Life Molecular.

Neuraceq contains Florbetaben F-18.

Neuraceq has a total of 1 drug patent out of which 0 drug patents have expired.

Neuraceq was authorised for market use on 19 March, 2014.

Neuraceq is available in solution;intravenous dosage forms.

Neuraceq can be used as neuraceq is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate p-amyloid neuritic plaque density in adult patients with cognitive impairment.

The generics of Neuraceq are possible to be released after 18 March, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7807135 LIFE MOLECULAR Stilbene derivatives and their use for binding and imaging amyloid plaques
Mar, 2029

(5 years from now)

Drugs and Companies using FLORBETABEN F-18 ingredient

Market Authorisation Date: 19 March, 2014

Treatment: Neuraceq is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate p-amyloid neuritic plaque density in adult patients with cognitive impairment

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

NEURACEQ family patents

7

United States

3

European Union

2

Israel

1

Portugal

1

Singapore

1

Spain

1

Brazil

1

Costa Rica

1

New Zealand

1

Norway

1

Mexico

1

China

1

Korea, Republic of

1

EA

1

South Africa

1

Lithuania

1

Canada

1

Japan

1

Luxembourg

1

Slovenia

1

Hungary

1

Ukraine

1

Poland

1

Australia

1

Denmark

1

Netherlands

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic